加鲁尼塞替联合新辅助放化疗治疗局部晚期直肠癌患者:单臂2期试验
这项研究者发起的单臂2期试验在两家医疗中心纳入38例局部晚期直肠腺癌患者,评估在氟尿嘧啶类放化疗前后加用TGF-β I型受体激酶抑制剂加鲁尼塞替的完全缓解率与安全性。结果显示12例(32%,单侧95%CI≥19%)达到完全缓解,常见3级不良事件为腹泻6例(16%)和血液学毒性7例(18%),无治疗相关死亡。作者认为该方案耐受良好,需在随机试验中进一步评估。
要点
- 38例局部晚期直肠癌患者接受加鲁尼塞替联合新辅助放化疗,完全缓解率为32%(单侧95%CI≥19%)。
- 3级不良事件以腹泻6例(16%)和血液学毒性7例(18%)常见,2例(5%)发生4级不良事件,无治疗相关死亡。
- 作者认为该联合方案耐受良好并改善完全缓解率,但需在随机试验中进一步评估。
核心结论
- 在局部晚期直肠癌患者中,新辅助放化疗加用加鲁尼塞替使完全缓解率提高至32%,耐受良好,需在随机试验中进一步评估。
研究设计与样本
- 研究者发起的单臂2期研究,在美国俄勒冈州波特兰的两家医疗中心开展。
- 纳入既往未治疗、局部晚期直肠腺癌(IIA-IIIC期或IV期)、ECOG体能状态0-2分、年龄18岁及以上的患者。
- 共入组38例参与者,主要终点为完全缓解率(手术患者病理完全缓解或非手术管理患者末次治疗后1年维持临床完全缓解的复合终点),安全性为共同主要终点,均在意向治疗人群评估。
- 试验注册号NCT02688712,处于活跃但未招募状态。
主要发现
- 38例参与者中12例(32%[单侧95%CI≥19%])达到完全缓解。
- 完成放化疗的35例患者中25例(71%)接受全直肠系膜切除术,其中5例(20%)为病理完全缓解。
- 10例(29%)患者接受非手术管理,其中3例(30%)最终选择全直肠系膜切除术,这3例中2例(67%)为病理完全缓解。
- 非手术管理组其余7例中5例(71%)在末次改良FOLFOX6输注后1年达到临床完全缓解。
- 治疗期间常见3级不良事件为腹泻6例(16%)和血液学毒性7例(18%);2例(5%)发生4级不良事件,1例与放化疗所致腹泻和脱水相关,另1例为术中缺血事件;无治疗相关死亡。
关键数值与推荐
- 加鲁尼塞替口服150 mg每日两次,共两个14天疗程,分别于氟尿嘧啶类放化疗前和期间给药。
- 放化疗方案为放疗期间静脉氟尿嘧啶225 mg/m2持续24小时每日7天每周,或放疗期间口服卡培他滨825 mg/m2每日两次每周5天;放疗为50.4-54.0 Gy分28-30次。
- 完全缓解者可选择非手术管理并接受改良FOLFOX6(每2周一次共8周期)或CAPEOX(每3周一次共4周期)。
- 未达完全缓解者接受手术切除。
临床怎么用
- 作者认为在局部晚期直肠癌新辅助放化疗中加用加鲁尼塞替使完全缓解率提高至32%且耐受良好,需在随机试验中进一步评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TGF-β is an immunosuppressive cytokine that is upregulated in colorectal cancer. TGF-β blockade improved response to chemoradiotherapy in preclinical models of colorectal adenocarcinoma. We aimed to test the hypothesis that adding the TGF-β type I receptor kinase inhibitor galunisertib to neoadjuvant chemoradiotherapy would improve pathological complete response rates in patients with locally advanced rectal cancer. METHODS: This was an investigator-initiated, single-arm, phase 2 study done in two medical centres in Portland (OR, USA). Eligible patients had previously untreated, locally advanced, rectal adenocarcinoma, stage IIA-IIIC or IV as per the American Joint Committee on Cancer; Eastern Cooperative Oncology Group status 0-2; and were aged 18 years or older. Participants completed two 14-day courses of oral galunisertib 150 mg twice daily, before and during fluorouracil-based chemoradiotherapy (intravenous fluorouracil 225 mg/m2 over 24 h daily 7 days per week during radiotherapy or oral capecitabine 825 mg/m2 twice per day 5 days per week during radiotherapy; radiotherapy consisted of 50·4-54·0 Gy in 28-30 fractions). 5-9 weeks later, patients underwent response assessment. Patients with a complete response could opt for non-operative management and proceed to modified FOLFOX6 (intravenous leucovorin 400 mg/m2 on day 1, intravenous fluorouracil 400 mg/m2 on day 1 then 2400 mg/m2 over 46 h, and intravenous oxaliplatin 85 mg/m2 on day 1 delivered every 2 weeks for eight cycles) or CAPEOX (intravenous oxaliplatin 130 mg/m2 on day 1 and oral capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks for four cycles). Patients with less than complete response underwent surgical resection. The primary endpoint was complete response rate, which was a composite of pathological complete response in patients who proceeded to surgery, or clinical complete response maintained at 1 year after last therapy in patients with non-operative management. Safety was a coprimary endpoint. Both endpoints were assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02688712, and is active but not recruiting. FINDINGS: Between Oct 19, 2016, and Aug 31, 2020, 38 participants were enrolled. 25 (71%) of the 35 patients who completed chemoradiotherapy proceeded to total mesorectal excision surgery, five (20%) of whom had pathological complete responses. Ten (29%) patients had non-operative management, three (30%) of whom ultimately chose to have total mesorectal excision. Two (67%) of those three patients had pathological complete responses. Of the remaining seven patients in the non-operative management group, five (71%) had clinical complete responses at 1 year after their last modified FOLFOX6 infusion. In total, 12 (32% [one-sided 95% CI ≥19%]) of 38 patients had a complete response. Common grade 3 adverse events during treatment included diarrhoea in six (16%) of 38 patients, and haematological toxicity in seven (18%) patients. Two (5%) patients had grade 4 adverse events, one related to chemoradiotherapy-induced diarrhoea and dehydration, and the other an intraoperative ischaemic event. No treatment-related deaths occurred. INTERPRETATION: The addition of galunisertib to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer improved the complete response rate to 32%, was well tolerated, and warrants further assessment in randomised trials. FUNDING: Eli Lilly via ExIST program, The Providence Foundation.
引用
- Yamazaki T, Gunderson AJ, Gilchrist M, et al. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol. 2022. PMID: 35952709. doi:10.1016/S1470-2045(22)00446-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。